AU StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

MESOBLAST LTD

2.000

-0.060-2.91%

Volume:8.50M

Turnover:16.99M

Market Cap:2.55B

PE:-13.63

High:2.060

Open:2.050

Low:1.970

Close:2.060

Loading ...

Overview Company News Filings

Mesoblast Receives US FDA Approval for Mesenchymal Stromal Cell Therapy; Shares Hit Four-Year High

MT Newswires Live

Mesoblast’s Ryoncil® Is the First U.S. FDA-Approved Mesenchymal Stromal Cell (MSC) Therapy

THOMSON REUTERS

Mesoblast share price rockets 30% on big US FDA news

Mesoblast ADRs Rise 22%, Company Joining Nasdaq Biotechnology Index

BRIEF-FDA Approves First Mesenchymal Stromal Cell Therapy To Treat Steroid-Refractory Acute Graft-Versus-Host Disease

Mesoblast Ltd-FDA Approves Mesoblast Ryoncil

THOMSON REUTERS

US FDA approves Mesoblast's cell therapy for graft-versus-host disease

FDA: Approved Ryoncil Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease in Pediatric Patients 2 Months of Age & Older

THOMSON REUTERS

FDA: Granted Approval of Ryoncil to Mesoblast, Inc.

THOMSON REUTERS

BRIEF-Mesoblast To Be Added To Nasdaq Biotechnology Index

Mesoblast to Be Added to Nasdaq Biotechnology Index

THOMSON REUTERS

Mesoblast to be Added to Nasdaq Biotechnology Index

MT Newswires Live

Mesoblast Ltd File Prospectus Relates to Offer, Sale From Time to Time by Selling Shareholder of up to 2 Mln Ordinary Shares

THOMSON REUTERS

RFK Jr. could prove a surprise boon for stem-cell stocks with pivotal year ahead

Stem Cells Poised for Success in 2025 as Regulatory Environment Looks More Favorable -- Market Talk

If you'd invested $5,000 in this ASX 300 healthcare stock a year ago, you'd now have $30,000!

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/MSB.AU/news?page=7"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"MSB.AU"},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MSB.AU\",,,,,undefined,":{"symbol":"MSB.AU","market":"AU","secType":"STK","nameCN":"MESOBLAST LTD","latestPrice":2,"timestamp":1741669920000,"preClose":2.06,"halted":0,"volume":8504845,"delay":0,"changeRate":-0.029126,"change":-0.06,"floatShares":738087712,"shares":1274447688,"eps":-0.14678471,"lyrEps":-0.141818,"pbRate":3.47,"amount":16991980,"amplitude":0.043689,"volumeRatio":0.7348421422333489,"dividePrice":0,"prevYearClose":3.1,"fiveDayClose":2.3,"twentyDayClose":2.98},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MSB.AU\",,,,,undefined,":{"symbol":"MSB.AU","floatShares":738087712,"roa":"-4.85%","roe":"-21.31%","lyrEps":-0.141818,"volumeRatio":0.7348421422333489,"shares":1274447688,"dividePrice":0,"high":2.06,"amplitude":0.043689,"preClose":2.06,"low":1.97,"week52Low":0.325,"pbRate":"3.47","psRate":"282.56","week52High":3.37,"institutionHeld":0,"latestPrice":2,"committee":0.129305,"eps":-0.14678471426753212,"divideRate":0,"volume":8504845,"delay":0,"ttmEps":-0.14678471426753212,"open":2.05,"prevYearClose":3.1,"prevWeekClose":2.09,"prevMonthClose":2.52,"prevQuarterClose":3.1,"fiveDayClose":2.3,"twentyDayClose":2.98,"sixtyDayClose":1.63},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/MSB.AU\",params:#limit:5,,,undefined,":[{"date":"2025-02-26","symbol":"MSB.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1740524400000,"name":null,"time":"","dateTimestamp":1740488400000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"MSB.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"MSB.AU\",pageSize:16,pageCount:7,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2492948162","title":"Mesoblast Receives US FDA Approval for Mesenchymal Stromal Cell Therapy; Shares Hit Four-Year High","url":"https://stock-news.laohu8.com/highlight/detail?id=2492948162","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492948162?lang=en_us&edition=fundamental","pubTime":"2024-12-19 08:53","pubTimestamp":1734569612,"startTime":"0","endTime":"0","summary":"Mesoblast  received US Food and Drug Administration approval for mesenchymal stromal cell  therapy, Ryoncil, according to a Thursday filing with the Australian bourse.Ryoncil is the only MSC therapy approved in the US for any indication and the only approved therapy for steroid-refractory acute graft-versus-host disease  in children two months and older, the filing said.SR-aGvHD is a stem cell transplant complication where a patient's disease doesn't respond to high-dose steroids.Shares rose nearly 33% in morning trade Thursday and earlier reached their highest since December 2020.Price : $2.63, Change: $+0.65, Percent Change: +32.83%","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7067","AUD","BK4575","LU0345774631.USD","MESO","BK7508","BK4125","BK7501","LU0426417589.USD","LU1043141123.HKD","BK4150","MSC","LU0994945656.USD","BK4139","LU0426412945.USD","LU2238339852.HKD","MSB.AU"],"gpt_icon":1},{"id":"2492161377","title":"Mesoblast’s Ryoncil® Is the First U.S. FDA-Approved Mesenchymal Stromal Cell (MSC) Therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2492161377","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492161377?lang=en_us&edition=fundamental","pubTime":"2024-12-19 08:09","pubTimestamp":1734566963,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241219:nFWN3NJ10R:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","BK7501","MESO","BK4139","BK7508","MSB.AU"],"gpt_icon":0},{"id":"2492697521","title":"Mesoblast share price rockets 30% on big US FDA news","url":"https://stock-news.laohu8.com/highlight/detail?id=2492697521","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492697521?lang=en_us&edition=fundamental","pubTime":"2024-12-19 07:46","pubTimestamp":1734565600,"startTime":"0","endTime":"0","summary":"The market is a sea of red on Thursday but that isn't stopping the Mesoblast Ltd  share price from rocketing. In morning trade, the allogeneic cellular medicines developer's shares are up 30% to a 52-week high of $2.57. Why is the Mesoblast share price shooting higher?","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2024/12/19/mesoblast-share-price-rockets-30-on-big-us-fda-news/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["BK4150","MSC","BK7508","BK7067","BK4139","BK7501","MESO","BK4575","MSB.AU"],"gpt_icon":1},{"id":"2492166865","title":"Mesoblast ADRs Rise 22%, Company Joining Nasdaq Biotechnology Index","url":"https://stock-news.laohu8.com/highlight/detail?id=2492166865","media":"Dow Jones","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492166865?lang=en_us&edition=fundamental","pubTime":"2024-12-19 07:20","pubTimestamp":1734564000,"startTime":"0","endTime":"0","summary":"The American depositary receipts of Mesoblast were trading higher after hours Wednesday following news the company will be added to the Nasdaq Biotechnology Index, effective Dec. 23.After the bell, the company's ADRs were trading 22% higher, at $14.98. They ended the day's regular session with a 2% loss, closing at $12.25.Mesoblast said it develops allogeneic  cellular medicines for the treatment of severe and life-threatening inflammatory conditions.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NDAQ","TSYW.SI","TQQQ","PSQ","BK7501","QLD","IE00BGHQF748.EUR","NVIW.SI","IE00B3QW5Z07.USD","BK4112","USAW.SI","USJW.SI","LU2210150020.SGD","MSB.AU","BK4588","MESO","LU2210149790.SGD","IE00BKPKM429.USD","IE00B64PRP62.GBP","BK4585","LU2095319765.USD","BK4139","BK7067","SQQQ","BK7508","MNQmain","QID",".IXIC","NQmain"],"gpt_icon":1},{"id":"2492116518","title":"BRIEF-FDA Approves First Mesenchymal Stromal Cell Therapy To Treat Steroid-Refractory Acute Graft-Versus-Host Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2492116518","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492116518?lang=en_us&edition=fundamental","pubTime":"2024-12-19 07:13","pubTimestamp":1734563639,"startTime":"0","endTime":"0","summary":"Dec 18  -    * FDA: APPROVES FIRST MESENCHYMAL STROMAL CELL THERAPY TO TREAT STEROID-REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE   * FDA: GRANTED APPROVAL OF RYONCIL TO MESOBLAST, INC.   * FDA: APPROVED RYONCIL TREATMENT OF STEROID-REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE IN PEDIATRIC PATIENTS 2 MONTHS OF AGE & OLDERSource text:    ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HST","BK4181","BK7067","MESO","BK7508","BK4139","BK4585","BK4588","BK7501","BK4218","MSB.AU"],"gpt_icon":0},{"id":"2492163080","title":"Mesoblast Ltd-FDA Approves Mesoblast Ryoncil","url":"https://stock-news.laohu8.com/highlight/detail?id=2492163080","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492163080?lang=en_us&edition=fundamental","pubTime":"2024-12-19 06:59","pubTimestamp":1734562744,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241218:nTUEK2SNG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7501","BK7067","BK7508","MSB.AU"],"gpt_icon":0},{"id":"2492997157","title":"US FDA approves Mesoblast's cell therapy for graft-versus-host disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2492997157","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492997157?lang=en_us&edition=fundamental","pubTime":"2024-12-19 05:50","pubTimestamp":1734558605,"startTime":"0","endTime":"0","summary":"US FDA approves Mesoblast's cell therapy for graft-versus-host diseaseDec 18  - The U.S. Food and Drug Administration on Wednesday approved Mesoblast's MSB.AX cell therapy for treating a type of complication that occurs after a stem cell or bone marrow transplant called graft-versus-host disease.  ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241218:nL4N3NJ1H9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","BK7501","MSB.AU","BK7508"],"gpt_icon":0},{"id":"2492615733","title":"FDA: Approved Ryoncil Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease in Pediatric Patients 2 Months of Age & Older","url":"https://stock-news.laohu8.com/highlight/detail?id=2492615733","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492615733?lang=en_us&edition=fundamental","pubTime":"2024-12-19 05:41","pubTimestamp":1734558078,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241218:nFWN3NJ10F:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MSB.AU","BK7067","BK7508","BK4139","BK7501","MESO"],"gpt_icon":0},{"id":"2492578581","title":"FDA: Granted Approval of Ryoncil to Mesoblast, Inc.","url":"https://stock-news.laohu8.com/highlight/detail?id=2492578581","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492578581?lang=en_us&edition=fundamental","pubTime":"2024-12-19 05:41","pubTimestamp":1734558078,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241218:nFWN3NJ10F:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7501","BK7508","MESO","MSB.AU","BK4139","BK7067"],"gpt_icon":0},{"id":"2492188611","title":"BRIEF-Mesoblast To Be Added To Nasdaq Biotechnology Index","url":"https://stock-news.laohu8.com/highlight/detail?id=2492188611","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492188611?lang=en_us&edition=fundamental","pubTime":"2024-12-18 20:56","pubTimestamp":1734526599,"startTime":"0","endTime":"0","summary":"BRIEF-Mesoblast To Be Added To Nasdaq Biotechnology IndexDec 18 (Reuters) - Mesoblast Ltd MSB.AX:MESOBLAST TO BE ADDED TO NASDAQ BIOTECHNOLOGY INDEXSource text: ID:nGNXc0QfgyFurther company coverage: MSB.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241218:nTUA28CKHJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BKPKM429.USD","LU2210150020.SGD","BK4588","BK4585","BK7501","MSB.AU","IE00B3QW5Z07.USD","IE00B64PRP62.GBP","NDAQ","BK7508","IE00BGHQF748.EUR","BK4112","BK7067","LU2095319765.USD","LU2210149790.SGD"],"gpt_icon":0},{"id":"2492900818","title":"Mesoblast to Be Added to Nasdaq Biotechnology Index","url":"https://stock-news.laohu8.com/highlight/detail?id=2492900818","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492900818?lang=en_us&edition=fundamental","pubTime":"2024-12-18 20:30","pubTimestamp":1734525000,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241218:nTUA28CKHJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4588","IE00B64PRP62.GBP","LU2210149790.SGD","BK7501","BK7067","BK4585","IE00BKPKM429.USD","BK4112","IE00BGHQF748.EUR","LU2095319765.USD","NDAQ","BK7508","MSB.AU","IE00B3QW5Z07.USD","LU2210150020.SGD"],"gpt_icon":0},{"id":"2492923107","title":"Mesoblast to be Added to Nasdaq Biotechnology Index","url":"https://stock-news.laohu8.com/highlight/detail?id=2492923107","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492923107?lang=en_us&edition=fundamental","pubTime":"2024-12-18 12:00","pubTimestamp":1734494447,"startTime":"0","endTime":"0","summary":"Mesoblast (ASX:MSB) will be added to the Nasdaq Biotechnology Index, effective after the US markets open on Dec. 23, according to a Wednesday filing with the Australian bourse.The company's shares rose nearly 2% in recent Wednesday trade.Price (AUD): $1.98, Change: $+0.04, Percent Change: +1.91%","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7501","LU0345774631.USD","MESO","LU0994945656.USD","IE00BKPKM429.USD","BK4112","MSB.AU","LU2210150020.SGD",".IXIC","BK4585","IE00BGHQF748.EUR","LU0426417589.USD","NDAQ","BK7508","XAO.AU","IE00B3QW5Z07.USD","NQmain","IE00B64PRP62.GBP","XJO.AU","LU2095319765.USD","BK4125","LU0426412945.USD","BK4588","LU2210149790.SGD","BK7067","LU1043141123.HKD","LU2238339852.HKD","XKO.AU","BK4139","AUD"],"gpt_icon":0},{"id":"2491583524","title":"Mesoblast Ltd File Prospectus Relates to Offer, Sale From Time to Time by Selling Shareholder of up to 2 Mln Ordinary Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2491583524","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2491583524?lang=en_us&edition=fundamental","pubTime":"2024-12-14 05:07","pubTimestamp":1734124029,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241213:nFWN3NE0T5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7501","MSB.AU","BK7067","BK7508"],"gpt_icon":0},{"id":"2491317453","title":"RFK Jr. could prove a surprise boon for stem-cell stocks with pivotal year ahead","url":"https://stock-news.laohu8.com/highlight/detail?id=2491317453","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2491317453?lang=en_us&edition=fundamental","pubTime":"2024-12-13 01:08","pubTimestamp":1734023280,"startTime":"0","endTime":"0","summary":"Maxim is expecting a breakthrough and names two stocks as beneficiaries. Stem-cell research is on the cusp of a breakthrough that could come as soon as 2025, and two biotech companies with promising therapies stand to gain, according to a new report from Maxim Group on Thursday.Mesoblast Ltd. , a Melbourne, Australia-based company that's seeking to develop cellular medicines for inflammatory diseases, and Capricor Therapeutics Inc. , a San Diego-based biotech developing cell-based treatments for rare diseases, are in the process of applying for Food and Drug Administration approvals that could come next year, according to Maxim analysts Jason McCarthy and Michael Okunewitch.The regenerative stem-cell-based therapy space experienced a boost in the mid-2010s that led to the emergence of a number of biotech companies eager to ride the wave, but the celebrations soon died down as companies faced regulatory setbacks as well as scientific ones, the analysts wrote.A more supportive health dep","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7501","MSB.AU","CAPR","BK7508","MESO","BK4139","BK7067"],"gpt_icon":1},{"id":"2490438792","title":"Stem Cells Poised for Success in 2025 as Regulatory Environment Looks More Favorable -- Market Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2490438792","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490438792?lang=en_us&edition=fundamental","pubTime":"2024-12-12 23:05","pubTimestamp":1734015900,"startTime":"0","endTime":"0","summary":"1005 ET - Regenerative stem cell-based therapies are poised for a breakthrough as the potential for approvals looks set to thrive in a more favorable regulatory environment, says Maxim Group's Jason McCarthy in a research note. The analyst says such therapies came onto the scene in the mid-2010s and contracted shortly afterwards, but can now step back into the limelight. McCarthy notes that two companies that have benefited from recent changes are Mesoblast and Capricor Therapeutics, with valuations of both rising significantly this year. He adds that RFK Jr., Trump's pick to run the Department of Health and Human Services, seems enthusiastic about stem cell research despite criticizing vaccines and fluoride. ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","BK7501","MSB.AU","BK7508","BK4139","MESO","CAPR"],"gpt_icon":1},{"id":"2490710819","title":"If you'd invested $5,000 in this ASX 300 healthcare stock a year ago, you'd now have $30,000!","url":"https://stock-news.laohu8.com/highlight/detail?id=2490710819","media":"MotleyFool","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490710819?lang=en_us&edition=fundamental","pubTime":"2024-12-12 06:30","pubTimestamp":1733956200,"startTime":"0","endTime":"0","summary":"Well, it's none other than biotech company Mesoblast Ltd . Yep, one year ago, you could have bought this ASX 300 stock for just 27 cents a pop. Today, those same shares are going for $1.63 each. That means if one had put $5,000 into Mesoblast shares in December of 2023, they would have been able to amass 18,518 shares . Today, those 18,518 shares would have a value of $30,184.34. Not a bad return for just one year of waiting. So, how has this ASX 300 healthcare stock delivered such an eye-watering gain in so little time?How has this ASX 300 healthcare stock rocketed 500% in a year?","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2024/12/12/if-youd-invested-5000-in-this-asx-300-healthcare-stock-a-year-ago-youd-now-have-30000/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["BK7095","PME.AU","WTC.AU","BK7507","BK7508","MSB.AU","XRO.AU","BHP.AU","BLA.AU","BK7511","BK7135","BK7503","CBA.AU","BK7501","BK7094","BK7067","BK7016"],"gpt_icon":0}],"pageSize":16,"totalPage":11,"pageCount":7,"totalSize":162}]}}